Source comparison
CJC-1295/Ipamorelin: Combination Comparison
| Formulation Variant | Half-Life | Dosing Frequency | GH Release Pattern | Receptor Tolerance Risk | Ipamorelin Synergy | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC + Ipamorelin | ~30 minutes (CJC), ~2 hours (Ipamorelin) | Daily or every other da
This comparison does not assign a generated winner or score.
- | Formulation Variant | Half-Life | Dosing Frequency | GH Release Pattern | Receptor Tolerance Risk | Ipamorelin Synergy | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC + Ipamorelin | ~30 minutes (CJC), ~2 hours (Ipamorelin) | Daily or every other day | Pulsatile, mimics endogenous rhythm | Low. Receptors maintain sensitivity across extended protocols | High. Ipamorelin amplifies discrete GHRH pulses effectively | Standard for multi-month research protocols; maintains natural GH dynamics without receptor downregulation || CJC-1295 with DAC + Ipamorelin | 6–8 days (CJC), ~2 hours (Ipamorelin) | Weekly | Continuous baseline elevation with blunted peaks | Moderate to high. Sustained GHRH signalling reduces receptor responsiveness after 12+ weeks | Low. Continuous CJC signal reduces discrete pulse amplitude Ipamorelin would otherwise amplify | Convenient for short-term protocols but undermines combination synergy in extended use || Ipamorelin alone | ~2 hours | Daily or twice dai